Myriad Genetics personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.

Research Grants 4 show all


$185.1K
2000

$818.8K
2007

$153K
2009

$961.5K
2015

Patents 851show all

  • 315
    A61K - Preparations for medical, dental, or toilet purposes
  • 294
    C07K - Peptides
  • 264
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 129
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 115
    A01K - Animal husbandry
  • 110
    C12N - Microorganisms or enzymes
  • 93
    C07D - Heterocyclic compounds
  • 38
    G16B - Bioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology
  • 21
    C40B - Combinatorial chemistry
  • 17
    C12Y - Enzymes

Clinical Trials 18show all

6Phase 34Phase 23N/A2Phase 1/Phase 2

SEC Filings show all


181
8-K

71
10-Q

23
10-K

1
D

Contact Information

320 Wakara Way
Salt Lake City, UT 84108
United States

Overview

Total FundingEmployeesLast Funding DateStatus
1001-5000Ipo